Europa Uomo publishes accessible version of EUPROMS findings

Europa Uomo has published a new presentation of the findings of its EUPROMS study, designed to inform men with prostate cancer, clinicians and decision-makers about the way treatments affect quality of life.

The pioneering EUPROMS study (Europa Uomo Patient Reported Outcome Study) is the first ever prostate cancer quality of life survey conducted by patients for patients. It is based on an online survey of 3,000 men with prostate cancer, exploring experiences of treatment and life afterwards.

Many results have already been presented to international conferences, and this month Europa Uomo Chairman will be discussing the latest findings at the virtual European Multidisciplinary Congress on Urological Cancers (13th-14th November) and the European Prostate Cancer Awareness Day online meeting (17th November).

The new presentation, featuring easy-to-understand graphics, is aimed at a general audience. It is accessible on the Europa Uomo website and available for download in a PowerPoint presentation. The EUPROMS web page can be translated using our website's "translate" button. The findings provide information that may:

• help patients and their doctors make decisions about treatments
• help in campaigning for early diagnosis of prostate cancer and promoting approaches such as active surveillance.

“We very much hope that our member organisations and men with prostate cancer will use this new presentation to spread important messages about the importance of early diagnosis,” says Europa Uomo Chairman André Deschamps. “It’s very clear from the data we present here that the more advanced the prostate cancer at diagnosis, the worse the effects of treatment on quality of life.”